Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sirolimus conversion for recurrent cutaneous squamous cell carcinoma in transplant recipients
NL-OMON28449Active, not recruiting
- Sponsor
- Wyeth
- Start
- Jan 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of sirolimus in cutaneous squamous cell carcinoma (cSCC) (2 arms), sponsored by Wyeth. Primary endpoint: Recurrence rate of biopsy-confirmed cutaneous squamous cell carcinoma. Started Jan 2004; status: active, not recruiting.
02
Drugs
sirolimus
03
Conditions
cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on NL-OMON28449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON28449.